Diffuse Large B cell lymphoma (DLBCL) is one of the most usual type of adult lymphoma with heterogeneousness in histological morphology, prognosis and clinical indications. Prior to this, several studies were carried out to determine the DLBCL subtype based on the analysis of the genome profile.However, classification based on assessment of genes related to the immune system has limited clinical significance for DLBCL. We systematically explored the DLBCL gene expression dataset and provided publicly available clinical information on patients with GEO and TCGA. In this research, 928 DLBCL samples from the Cancer Genome Atlas (TCGA) were applied, we calculated 29 immune-related genomes' enrichment levels in each sample and stratified them into high immunity that was based on ssGSEA score (Immunity_H, n=323,68.7%), moderate (Immunity_M, n= 135, 28.7%) and low (Immunity_L, n= 12,2.6%). The ESTIMATE algorithm was used to calculate matrix score (range: -1,800.51,901.99), immunity score (range: -1,476.28,780.33), estimated score (range: -2,618.28,098.14), and tumor purity (range:0.216 0.976), All of them were significantly correlated with immune subtypes (Kruskal Wallis test, P < 0.001). At the same time, the correlation of related genes was analyzed by immunohistochemistry staining. In addition, DLBCL cells were cultured in transfected and vitro with siRNA to verify correlation analysis and gene expression. Finally, human peripheral blood lymphocytes were incubated with DLBCL cells, and stained. Flow cytometry was applied to analyze genes' influence on immune function.By analysis, immune checkpoint and HLA gene expression levels were higher in the Immunity_H group (Kruskal Wallis test, P < 0.05). The levels of Tfhs (follicular helper T cells), Monocytes, CD8+ T cells, M1 Macrophages, M2 Macrophages, CD4+ memory activated T cells, were the most excellent in Immunity_H, and total survival rate was higher in the Immunity_L. The GO term discovered in Immunity_H is connected with immunity. Through analysis, IRF4 (MUM1) was identified by us as immunotherapeutic target and a potential prognostic marker for DLBCL, which was made sure by using molecular biology experimentations. To conclude, immunosignature made a connection between DLBCL subtypes play a position in DLBCL prognostic stratification. Immunocharacteristics-related DLBCL subtypes' construction predicts expected patient results and supplies conceivable immunotherapy candida.